Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

TICD see tumor-induced cell death
TILNs see tumor-infiltrated lymph nodes
TILs see tumor-infiltrating lymphocytes
TIMP see tumor inhibitor of metalloproteinase
TLR family, PRR receptors 271f.
TNF see tumor necrosis factor
TNF-a
±, dendritic cells 184f.
±, MHC class I antigens 79
TNF-related activation induced cytokine
receptor (TRANCE-R) 181
tolerance
±, central 211, 223
±, immunobiological 206f.
±, peripheral 263
toll-like receptors, dendritic cells 180
total body radiation 299
toxin moiety, immunotoxins 351
toxins
±, bacterial see bacterial toxins
±, chimeric see chimeric toxins
±, Coley's see Coley's toxins
±, diphteria see diphteria toxin
±, endo- see endotoxins
±, exo- see pseudomonas exotoxin
±, immuno- see immunotoxins
±, lympho- see lymphotoxins
TRAIL-TRAIL receptor pathway, tumor microenvironment
112
TRANCE-R see TNF-related activation induced
cytokine receptor
transferrin receptor 361
transforming growth factor (TGF) 100
transforming growth factor (TGF)-b 119±125
±, effects of IL-10 165f.
±, immunotoxins 350
transgenic mice 365
transplant-related mortality (TRM) 300
transplantation
±, allogenic 197, 361
±, bone marrow see bone marrow transplantation
transporter associated with antigen processing
(TAP) 31, 34, 60
±, MHC class I 69±73
tripartite CR 289, 293
TRM see transplant-related mortality
TRP-2 antigen 334f.
tumor antigen-associated epitopes 220
tumor antigen responses 209
tumor antigenicity 3±55, 155, 231ff.
tumor antigens 17±29
±, definition 224
±, HSPs 254
Index
tumor-associated antigens (TAAs) 5 f., 66, 209,
220f., 231ff., 347
±, dendritic cells 194±197
±, HCV 236f.
±, HLA class II restricted 49f.
±, immunocytokines 311f.
±, processing and presentation 30±39
±, relevance of MHC class I alterations 76f.
±, tumor microenvironment 96
tumor-associated DC (TADC) 105f.
tumor-associated macrophages (TAM) 107f.
tumor-associated T cell epitopes 231ff.
tumor-associated T cells (TATC) 99
tumor cell killing 218f.
tumor-derived HSP/peptide complexes
257f.
tumor-derived molecules, immunosuppressive
factors 120
tumor escape 99, 195
tumor growth, immunosurveillance 84f.
tumor-immune system interaction 65f.
tumor-induced apoptosis 105
±, T cells 110
tumor-induced cell death (TICD) 110, 114
tumor-induced immunosuppression 107
tumor-infiltrated lymph nodes (TILNs)
46±49
tumor-infiltrating lymphocytes (TILs)
41, 46±49, 333
±, microenvironment 97±101
tumor inhibition, effects of IL-10 165f.
tumor inhibitor of metalloproteinase (TIMP)
113
±, effects of IL-10 165
tumor lysates, HCV 240
tumor microenvironment 47, 95±118, 311,
327, 340
tumor models 218±221
±, see also models
tumor necrosis factor (TNF) 101, 109, 112f.
tumor penetration 355
tumor progression, and immune system
95ff.
tumor promotion, effects of IL-10 164f.
tumor regression antigens 5, 42
tumor rejection antigens 5
tumor-shed antigens, immunosuppressive
factors 120, 134
tumor-specific peptides 365
tumor-specific vaccines, HSPs 256ff.
tumor-testis antigens 231
tumor vaccines, non-individualized 332
tumors
±, solid 360f.
407